-
-
TSA rationalizes airport security, emphasizing risk-based priorities
TSA emphasizes technology, explosives detection
-
-
<span style=
Direct funding of companies and pipeline approach to BioShield program defy convention
-
-
Trust for Americas Health releases state-by-state bioterror scores
Most states failing, according to new report
-
-
North Carolina bioterror surveillance system receives health IT award
NC DETECT wins award for helping public health officials to monitor disease outbreak
-
-
Final food security rule issued by FDA under Bioterrorism Act
New rule covers record-keeping related to human and animal food
-
-
Bioterrorism chief Stewart Simonson taking heat
Simonson is on the losing end of this battle
-
-
-
Congress impatient with BioShields anti-radiation moves
HHS under heavy scrutiny from industry and Congress
-
-
-
RAE shows personal radiation detector
RAE shows intrinsically safe personal detection equipment
-
-
-
-
-
The long view
Are We Ready for a ‘DeepSeek for Bioweapons’?
Anthropic’s Claude 4 is a warning sign: AI that can help build bioweapons is coming, and could be widely available soon. Steven Adler writes that we need to be prepared for the consequences: “like a freely downloadable ‘DeepSeek for bioweapons,’ available across the internet, loadable to the computer of any amateur scientist who wishes to cause mass harm. With Anthropic’s Claude Opus 4 having finally triggered this level of safety risk, the clock is now ticking.”
A Brief History of Federal Funding for Basic Science
Biomedical science in the United States is at a crossroads. For 75 years, the federal government has partnered with academic institutions, fueling discoveries that have transformed medicine and saved lives. Recent moves by the Trump administration — including funding cuts and proposed changes to how research support is allocated — now threaten this legacy.
Vaccine Integrity Project Says New FDA Rules on COVID-19 Vaccines Show Lack of Consensus, Clarity
Sidestepping both the FDA’s own Vaccines and Related Biological Products Advisory Committee and the CDC’s Advisory Committee on Immunization Practices (ACIP), two Trump-appointed FDA leaders penned an opinion piece in the New England Journal of Medicine to announce new, more restrictive, COVID-19 vaccine recommendations. Critics say that not seeking broad input into the new policy, which would help FDA to understand its implications, feasibility, and the potential for unintended consequences, amounts to policy by proclamation.